US EditionAkero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
Summary by stocktitan.net
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
stocktitan.netReposted by 
ADKhabar
ADKhabarAkero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
Akero Therapeutics (NASDAQ: AKRO) presented new analyses of their Phase 2b HARMONY trial for efruxifermin (EFX) in pre-cirrhotic MASH patients at EASL Congress 2025. The study utilized HistoIndex's AI-based qFibrosis® digital pathology analysis alongside conventional methods. Key findings showed that among patients treated with 50mg EFX, over 50% were classified as responders across all three endpoints (qFibrosis®, ELF test score, and FibroScan®…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
